Hepatorenal Syndrome Market Positioned for Steady Growth Through 2034, DelveInsight Finds

The Hepatorenal Syndrome (HRS) market is expected to grow at a steady CAGR during the forecast period (2025–2034) from approximately 1.7 billion in 2023. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Hepatorenal Syndrome landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Hepatorenal Syndrome market is increasingly guided by vasoconstrictor-driven therapeutic strategies. TERLIVAZ (terlipressin), developed by Mallinckrodt Pharmaceuticals, represents the only FDA-approved treatment specifically indicated for Hepatorenal Syndrome and is recommended as the preferred vasoconstrictor therapy by the American Association for the Study of Liver Diseases (AASLD) and the American College of Gastroenterology (ACG) guidelines.

Hepatorenal Syndrome is a life-threatening complication that occurs in patients with advanced liver disease and cirrhosis. It was found that approximately 40% of patients with cirrhosis and ascites develop Hepatorenal Syndrome during the natural history of their disease. The cumulative probability of developing Hepatorenal Syndrome at 1 year is approximately 18% and at 5 years is approximately 39% in patients with decompensated liver disease. HRS-AKI (acute kidney injury) accounts for approximately 11% of AKI in hospitalized cirrhotic patients with refractory ascites and is associated with high mortality.​

In Japan, Hepatorenal Syndrome outcomes reveal significant mortality rates, with over 65% of patients dying or undergoing liver transplantation during hospitalization. Albumin was administered to over 50% of participants, while dopamine was more frequently used as a vasoconstrictor in clinical practice despite noradrenaline being recommended in Japanese clinical guidelines.

DelveInsight's report, "Hepatorenal Syndrome Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Hepatorenal Syndrome landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Hepatorenal Syndrome market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Hepatorenal Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, visit Hepatorenal Syndrome Market Insights

Some of the key facts of the Hepatorenal Syndrome Market Report:

• Key Hepatorenal Syndrome Companies: Mallinckrodt Pharmaceuticals, Cumberland Pharmaceuticals, Ocelot Bio Inc., Noorik Biopharmaceuticals, Ferring Pharmaceuticals, Novartis, and others.
• Key Hepatorenal Syndrome Therapies: TERLIVAZ (terlipressin), Ambrisentan, OCE-205, Ifetroban Injection, Midodrine, and others.
• The Hepatorenal Syndrome market is expected to surge due to increasing awareness, advancement in diagnostic technologies, and the development of novel therapies during the forecast period. Furthermore, launching various multiple-stage Hepatorenal Syndrome pipeline products will significantly revolutionize the Hepatorenal Syndrome market dynamics.

Hepatorenal Syndrome Overview

Hepatorenal Syndrome (HRS) is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. Hepatorenal Syndrome is the extreme form of kidney injury in patients with cirrhosis, which is caused due to a reduction in renal blood flow unresponsive to volume expansion. The condition is characterized by a marked reduction in glomerular filtration rate and renal plasma flow, in the absence of other structural causes of renal failure. Hepatorenal Syndrome is now classified into HRS-AKI (acute kidney injury, formerly Type 1 HRS) characterized by rapid deterioration of kidney function, and HRS-NAKI including HRS-AKD and HRS-CKD (formerly Type 2 HRS) representing more gradual impairment. Risk factors include advanced cirrhosis, portal hypertension, spontaneous bacterial peritonitis, and hyponatremia. Liver transplantation remains the only curative option for patients failing to respond to medical therapies.

Key Trends in Hepatorenal Syndrome Therapeutics Market:

• Rising Adoption of Vasoconstrictor Therapies: Increasing use of terlipressin as the preferred first-line treatment in combination with albumin for HRS-AKI.
• Precision Medicine & Biomarker Development: Enhanced diagnostic tools and biomarker-based therapies enabling early detection and personalized treatment strategies.
• Pipeline Innovation: Development of novel therapies, including endothelin receptor antagonists, selective vasopressin receptor agonists, and thromboxane receptor antagonists to address treatment resistance and unmet needs.
• Updated Treatment Guidelines: Recent ICA-ADQI consensus statements reshaping diagnosis criteria to recognize kidney injury earlier and start treatment sooner.​
• Market Growth in Emerging Regions: Rising Hepatorenal Syndrome prevalence due to increasing liver disease burden and improved healthcare infrastructure
• Focus on Bridging to Transplant: Development of therapies aimed at stabilizing patients while awaiting liver transplantation, the only definitive cure.

Hepatorenal Syndrome Epidemiology

The Hepatorenal Syndrome epidemiology section of the report provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes type-specific distribution, regional and global trends, and data on HRS-AKI and HRS-NAKI classifications. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Hepatorenal Syndrome and plan targeted interventions, research, and treatment strategies.

Hepatorenal Syndrome Epidemiology Segmentation:

The Hepatorenal Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Hepatorenal Syndrome
• Total Diagnosed Prevalent Cases of Hepatorenal Syndrome
• Type-specific Cases of Hepatorenal Syndrome

Download the report to understand which factors are driving Hepatorenal Syndrome epidemiology trends @ Hepatorenal Syndrome market drivers

Recent Development In The Hepatorenal Syndrome Treatment Landscape:

• In January 2025, Noorik Biopharmaceuticals announced a clinical trial to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome. This clinical trial will compare the safety and effects of ambrisentan to terlipressin, which is commonly used to treat patients with hepatorenal syndrome.

• In October 2025, Mallinckrodt announced the presentation of data on TERLIVAZ (terlipressin) in patients with hepatorenal syndrome with rapid reduction in kidney function at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting.

Hepatorenal Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatorenal Syndrome market or expected to get launched during the study period. The analysis covers Hepatorenal Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatorenal Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatorenal Syndrome Therapies and Key Companies

• TERLIVAZ (terlipressin): Mallinckrodt Pharmaceuticals
• Ambrisentan (N-003): Noorik Biopharmaceuticals
• OCE-205: Ocelot Bio Inc.
• Ifetroban Injection: Cumberland Pharmaceuticals
• Midodrine + Octreotide: Various companies

To know more about Hepatorenal Syndrome companies working in the treatment market, visit @ Hepatorenal Syndrome Competitive Landscape

Hepatorenal Syndrome Market Drivers

• Increasing prevalence of liver cirrhosis and chronic liver diseases globally, driving demand for effective therapies
• Rising healthcare expenditure and government initiatives supporting liver disease management
• FDA approval of TERLIVAZ (terlipressin) as the first and only approved treatment for HRS-AKI, expanding treatment options
• Advancements in diagnostic technologies enabling earlier Hepatorenal Syndrome detection and intervention
• Growing awareness and updated treatment guidelines supporting standardized therapeutic approaches
• Development of novel pipeline therapies addressing unmet needs and treatment resistance

Hepatorenal Syndrome Market Barriers

• High mortality rates and poor prognosis without liver transplantation limiting treatment success
• Limited effective treatment options beyond vasoconstrictor therapy and transplantation
• High cost of therapies and hospitalization requirements reducing patient access
• Complex diagnosis criteria and Hepatorenal Syndrome being a diagnosis of exclusion potentially delaying treatment initiation
• Adverse effects and safety concerns associated with vasoconstrictor therapies including respiratory failure risk
• Limited availability of liver donors for transplantation, the only curative treatment option

Scope of the Hepatorenal Syndrome Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hepatorenal Syndrome Companies: Mallinckrodt Pharmaceuticals, Cumberland Pharmaceuticals, Ocelot Bio Inc., Noorik Biopharmaceuticals, Ferring Pharmaceuticals, Novartis, and others
• Key Hepatorenal Syndrome Therapies: TERLIVAZ (terlipressin), Ambrisentan, OCE-205, Ifetroban Injection, Midodrine, and others
• Hepatorenal Syndrome Therapeutic Assessment: Hepatorenal Syndrome current marketed and emerging therapies
• Hepatorenal Syndrome Market Dynamics: Hepatorenal Syndrome market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatorenal Syndrome Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement​

Discover more about therapies set to grab major Hepatorenal Syndrome market share @ Hepatorenal Syndrome Therapies